TABLE 1.
Demographic and clinical characteristics of patients and drug resistance patterns at diagnosis in the four studied sites
| Variablea | Value for each study site |
Total (n = 878) | χ2 value | P value | |||
|---|---|---|---|---|---|---|---|
| GY (n = 254) | DQ (n = 216) | GJ (n = 237) | RO (n = 171) | ||||
| Male, no. (%) | 184 (72.4) | 152 (70.4) | 157 (66.2) | 115 (67.3) | 608 (69.2) | 2.668 | 0.446 |
| Age, yrs (mean ± SD) | 45.3 ± 19.5 | 48.2 ± 18.0 | 47.5 ± 19.5 | 49.1 ± 19.9 | 47.3 ± 19.2 | 1.626b | 0.182 |
| Previously treated, no. (%) | 56 (22.0) | 41 (19.0) | 52 (21.9) | 36 (21.1) | 185 (21.1) | 0.820 | 0.845 |
| Sputum smear positive, no. (%) | 159 (62.6) | 140 (64.8) | 143 (60.3) | 91 (53.2) | 533 (60.7) | 5.945 | 0.114 |
| Cavity, no. (%) | 70 (27.6) | 47 (21.8) | 62 (26.2) | 48 (28.1) | 227 (25.9) | 2.724 | 0.436 |
| First-line drug susceptibility, no. (%) | |||||||
| DS | 116 (45.7) | 134 (62.0) | 128 (54.0) | 100 (58.5) | 478 (54.4) | 22.47 | 0.001c |
| MDR | 34 (13.4) | 25 (11.6) | 40 (16.9) | 30 (17.5) | 129 (14.7) | ||
| ODR | 104 (40.9) | 57 (26.4) | 69 (29.1) | 41 (24.0) | 271 (30.9) | ||
| PZA susceptibility, no. (%) | |||||||
| PZA resistance | 44 (17.3) | 37 (17.1) | 38 (16.0) | 28 (16.4) | 147 (16.7) | 0.187 | 0.980 |
| PZA monoresistance | 12 (4.7) | 13 (6.0) | 6 (2.5) | 6 (3.5) | 37 (4.2) | 3.779 | 0.286 |
| PZA resistance/MDR | 8 (3.1) | 9 (4.2) | 11 (4.6) | 11 (6.4) | 39 (4.4) | 2.657 | 0.448 |
a
DS, drug susceptible to isoniazid, rifampin, ethambutol, and streptomycin; MDR, multidrug resistant; ODR, other first-line drug resistant; PZA, pyrazinamide.
b
F value in ANOVA test.
c
P < 0.05.